It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
High Court builds up momentum to determine FRAND Licensing terms (PART 1 of 2)
-
EPO: T0025/13, European Patent Office (EPO), Board of Appeal, T0025/13, 20 November 2014
-
Compulsory Licensing Australia
-
USA: IPCom GmbH & Co. v. HTC Corp., United States Court of Appeals, Federal Circuit, No. 2015-1754, 11 July 2016
-
DE, UK, EPO: A Few Thoughts on Constitutional Matters
-
Brazilian Senate Approves Bill on the Compulsory Licensing of COVID-19 Vaccines’ Patents
-
Inventive step, Priority right, Second Medical Use, Sufficiency of disclosure, United Kingdom, Validity
Hospira clears the way for generic Herceptin
-
Annotation of patents: a threat to second medical use patents in Brazil?
-
Will Father Christmas bring a new Spanish Patent Act for 2014?
-
Optis v Apple: English Court gets to the core of the saga